Trials / Completed
CompletedNCT04508413
A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function
An Exploratory, 14-week, Open-label Clinical Food Study to Evaluate the Effects of KB295 in Adult Patients With Ulcerative Colitis (UC) Presenting With Mild-to-moderate UC Symptoms
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Kaleido Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This exploratory, open-label clinical study aims to explore the effects of KB295, a novel glycan, on adult patients with ulcerative colitis (UC) presenting with mild-to-moderate UC symptoms
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | KB295 | KB295 is a novel glycan |
Timeline
- Start date
- 2020-08-12
- Primary completion
- 2021-11-29
- Completion
- 2021-11-29
- First posted
- 2020-08-11
- Last updated
- 2022-01-24
Locations
3 sites across 2 countries: United States, Ireland
Source: ClinicalTrials.gov record NCT04508413. Inclusion in this directory is not an endorsement.